SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Personalized Heart Digital Twins Detect Substrate Abnormalities in Scar-Dependent Ventricular Tachycardia.

Waight, MC; Prakosa, A; Li, AC; Bunce, N; Marciniak, A; Trayanova, NA; Saba, MM (2025) Personalized Heart Digital Twins Detect Substrate Abnormalities in Scar-Dependent Ventricular Tachycardia. Circulation, 151 (8). pp. 521-533. ISSN 1524-4539 https://doi.org/10.1161/CIRCULATIONAHA.124.070526
SGUL Authors: Saba, Magdi Mohamed

[img] PDF Published Version
Available under License Creative Commons Attribution.

Download (4MB)
[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution.

Download (733kB) | Preview
[img]
Preview
PDF (Supplemental material) Supplemental Material
Download (725kB) | Preview

Abstract

BACKGROUND: Current outcomes from catheter ablation for scar-dependent ventricular tachycardia (VT) are limited by high recurrence rates and long procedure durations. Personalized heart digital twin technology presents a noninvasive method of predicting critical substrate in VT, and its integration into clinical VT ablation offers a promising solution. The accuracy of the predictions of digital twins to detect invasive substrate abnormalities is unknown. We present the first prospective analysis of digital twin technology in predicting critical substrate abnormalities in VT. METHODS: Heart digital twin models were created from 18 patients with scar-dependent VT undergoing catheter ablation. Contrast-enhanced cardiac magnetic resonance images were used to reconstruct finite-element meshes, onto which regional electrophysiological properties were applied. Rapid-pacing protocols were used to induce VTs and to define the VT circuits. Predicted optimum ablation sites to terminate all VTs in the models were identified. Invasive substrate mapping was performed, and the digital twins were merged with the electroanatomical map. Electrogram abnormalities and regions of conduction slowing were compared between digital twin-predicted sites and nonpredicted areas. RESULTS: Electrogram abnormalities were significantly more frequent in digital twin-predicted sites compared with nonpredicted sites (468/1029 [45.5%] versus 519/1611 [32.2%]; P<0.001). Electrogram duration was longer at predicted sites compared with nonpredicted sites (82.0±25.9 milliseconds versus 69.7±22.3 milliseconds; P<0.001). Digital twins correctly identified 21 of 26 (80.8%) deceleration zones seen on isochronal late activation mapping. CONCLUSIONS: Digital twin-predicted sites display a higher prevalence of abnormal and prolonged electrograms compared with nonpredicted sites and accurately identify regions of conduction slowing. Digital twin technology may help improve substrate-based VT ablation. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04632394.

Item Type: Article
Additional Information: © 2025 The Authors. Circulation is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Keywords: catheter ablation, electrophysiologic techniques, cardiac, magnetic resonance imaging, tachycardia, ventricular, 1102 Cardiorespiratory Medicine and Haematology, 1103 Clinical Sciences, 1117 Public Health and Health Services, Cardiovascular System & Hematology
SGUL Research Institute / Research Centre: Academic Structure > Cardiovascular & Genomics Research Institute
Academic Structure > Cardiovascular & Genomics Research Institute > Clinical Cardiology
Journal or Publication Title: Circulation
ISSN: 1524-4539
Language: eng
Publisher License: Creative Commons: Attribution 4.0
Projects:
Project IDFunderFunder ID
RES 20 21 001St George's Hospital CharityUNSPECIFIED
R01HL142496National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
R01HL166759National Institutes of Healthhttp://dx.doi.org/10.13039/100000002
UNSPECIFIEDLeducq FoundationUNSPECIFIED
UNSPECIFIEDAbbott Laboratorieshttp://dx.doi.org/10.13039/100001316
PubMed ID: 39758009
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/117073
Publisher's version: https://doi.org/10.1161/CIRCULATIONAHA.124.070526

Actions (login required)

Edit Item Edit Item